Laboratory Medicine ›› 2024, Vol. 39 ›› Issue (1): 60-67.DOI: 10.3969/j.issn.1673-8640.2024.01.011
Previous Articles Next Articles
ZHANG Xiaoling, JIN Yao, LI Sufang, PENG Haiying
Received:
2022-06-17
Revised:
2023-08-17
Online:
2024-01-30
Published:
2024-03-04
CLC Number:
ZHANG Xiaoling, JIN Yao, LI Sufang, PENG Haiying. Synergistic diagnosis of THR mRNA and ALCAT1 in hyperthyroidism heart disease[J]. Laboratory Medicine, 2024, 39(1): 60-67.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2024.01.011
组别 | 例数 | THRα1 mRNA | THRβ1 mRNA | ALCAT1/(ng·L-1) |
---|---|---|---|---|
甲亢性心脏病组 | 69 | 2.71±0.66 | 4.20±0.63 | 1.39±0.27 |
单纯甲亢组 | 69 | 2.52±0.54 | 3.45±0.69* | 1.15±0.25* |
非甲亢性心脏病组 | 69 | 2.10±0.41*### | 2.98±0.61*### | 1.08±0.11*# |
正常对照组 | 69 | 1.89±0.43*###△△ | 2.68±0.58*###△△ | 1.04±0.12*##△ |
F值 | 36.154 | 76.571 | 39.777 | |
P值 | <0.001 | <0.001 | <0.001 |
组别 | 例数 | THRα1 mRNA | THRβ1 mRNA | ALCAT1/(ng·L-1) |
---|---|---|---|---|
甲亢性心脏病组 | 69 | 2.71±0.66 | 4.20±0.63 | 1.39±0.27 |
单纯甲亢组 | 69 | 2.52±0.54 | 3.45±0.69* | 1.15±0.25* |
非甲亢性心脏病组 | 69 | 2.10±0.41*### | 2.98±0.61*### | 1.08±0.11*# |
正常对照组 | 69 | 1.89±0.43*###△△ | 2.68±0.58*###△△ | 1.04±0.12*##△ |
F值 | 36.154 | 76.571 | 39.777 | |
P值 | <0.001 | <0.001 | <0.001 |
组别 | 例数 | 性别/% | 年龄 | 甲状腺功能亢进病程 | 吸烟史/ [例(%)] | |||
---|---|---|---|---|---|---|---|---|
男/ [例(%)] | 女/ [例(%)] | <60岁/ [例(%)] | ≥60岁/ [例(%)] | <6年/ [例(%)] | ≥6年/ [例(%)] | |||
甲亢性心脏组 | 69 | 14(20.29) | 55(79.71) | 42(60.87) | 27(39.13) | 41(59.42) | 28(40.58) | 41(59.42) |
单纯甲亢组 | 69 | 16(23.19) | 53(76.81) | 45(65.22) | 24(34.78) | 54(78.26) | 15(21.74) | 38(55.07) |
统计值 | 0.17 | 0.28 | 5.709 | 0.267 | ||||
P值 | 0.68 | 0.597 | 0.017 | 0.606 | ||||
组别 | 饮酒史/ [例(%)] | BMI | ||||||
<18.5 kg·m-2/ [例(%)] | 18.5~23.9 kg·m-2/ [例(%)] | 24.0~27.9 kg·m-2/ [例(%)] | ≥28.0 kg·m-2/ [例(%)] | |||||
甲亢性心脏组 | 52(75.36) | 15(21.74) | 33(47.83) | 13(18.84) | 8(11.59) | |||
单纯甲亢组 | 50(72.46) | 12(17.39) | 36(52.17) | 15(21.74) | 6(8.70) | |||
统计值 | 0.15 | 0.892 | ||||||
P值 | 0.698 | 0.827 | ||||||
组别 | 甲状腺功能 亢进家族史/ [例(%)] | 心脏病 家族史/ [例(%)] | 收缩压/ kPa | 舒张压/ kPa | 乳酸脱氢酶/ (U/L) | FPG/ (mmol·L-1) | 2 h PG/ (mmol·L-1) | |
甲亢性心脏组 | 10(14.49) | 8(13.11) | 16.50±1.23 | 13.89±1.02 | 213.56±46.38 | 5.02±0.49 | 7.05±0.82 | |
单纯甲亢组 | 8(11.59) | 5(8.20) | 16.20±1.19 | 13.67±1.07 | 198.65±48.22 | 4.89±0.52 | 6.82±0.78 | |
统计值 | 0.256 | 0.775 | 1.456 | 1.236 | 1.851 | 1.511 | 1.688 | |
P值 | 0.613 | 0.379 | 0.148 | 0.219 | 0.066 | 0.133 | 0.094 | |
组别 | TC/ (mmol·L-1) | TG/ (mmol·L-1) | CK-MB mass/ (μg·L-1) | LDL-C/ (mmol·L-1) | HD-C/L (mmol/·L-1) | FT3/ (pmol·L-1) | ||
甲亢性心脏组 | 4.05±1.21 | 1.11±0.40 | 3.22±0.91 | 2.06±0.56 | 1.18±0.32 | 7.54±1.32 | ||
单纯甲亢组 | 4.32±1.09 | 1.23±0.35 | 2.94±0.80 | 1.89±0.61 | 1.09±0.34 | 6.58±1.19 | ||
统计值 | 1.377 | 1.875 | 1.92 | 1.705 | 1.601 | 4.487 | ||
P值 | 0.171 | 0.063 | 0.057 | 0.09 | 0.112 | <0.001 | ||
组别 | FT4/(pmol·L-1) | TSH/(mIU·L-1) | TT3/(μg·L-1) | TT4/(μg·L-1) | THRβ1 mRNA | ALCAT1/(ng·L-1) | ||
甲亢性心脏组 | 19.03±4.10 | 1.49±0.46 | 2.57±0.72 | 130.24±24.31 | 4.20±0.63 | 1.39±0.27 | ||
单纯甲亢组 | 16.84±3.87 | 1.73±0.42 | 2.16±0.69 | 114.98±26.07 | 3.45±0.69 | 1.15±0.25 | ||
统计值 | 3.227 | 3.201 | 3.415 | 3.556 | 6.668 | 5.418 | ||
P值 | 0.002 | 0.002 | 0.001 | 0.001 | <0.001 | <0.001 |
组别 | 例数 | 性别/% | 年龄 | 甲状腺功能亢进病程 | 吸烟史/ [例(%)] | |||
---|---|---|---|---|---|---|---|---|
男/ [例(%)] | 女/ [例(%)] | <60岁/ [例(%)] | ≥60岁/ [例(%)] | <6年/ [例(%)] | ≥6年/ [例(%)] | |||
甲亢性心脏组 | 69 | 14(20.29) | 55(79.71) | 42(60.87) | 27(39.13) | 41(59.42) | 28(40.58) | 41(59.42) |
单纯甲亢组 | 69 | 16(23.19) | 53(76.81) | 45(65.22) | 24(34.78) | 54(78.26) | 15(21.74) | 38(55.07) |
统计值 | 0.17 | 0.28 | 5.709 | 0.267 | ||||
P值 | 0.68 | 0.597 | 0.017 | 0.606 | ||||
组别 | 饮酒史/ [例(%)] | BMI | ||||||
<18.5 kg·m-2/ [例(%)] | 18.5~23.9 kg·m-2/ [例(%)] | 24.0~27.9 kg·m-2/ [例(%)] | ≥28.0 kg·m-2/ [例(%)] | |||||
甲亢性心脏组 | 52(75.36) | 15(21.74) | 33(47.83) | 13(18.84) | 8(11.59) | |||
单纯甲亢组 | 50(72.46) | 12(17.39) | 36(52.17) | 15(21.74) | 6(8.70) | |||
统计值 | 0.15 | 0.892 | ||||||
P值 | 0.698 | 0.827 | ||||||
组别 | 甲状腺功能 亢进家族史/ [例(%)] | 心脏病 家族史/ [例(%)] | 收缩压/ kPa | 舒张压/ kPa | 乳酸脱氢酶/ (U/L) | FPG/ (mmol·L-1) | 2 h PG/ (mmol·L-1) | |
甲亢性心脏组 | 10(14.49) | 8(13.11) | 16.50±1.23 | 13.89±1.02 | 213.56±46.38 | 5.02±0.49 | 7.05±0.82 | |
单纯甲亢组 | 8(11.59) | 5(8.20) | 16.20±1.19 | 13.67±1.07 | 198.65±48.22 | 4.89±0.52 | 6.82±0.78 | |
统计值 | 0.256 | 0.775 | 1.456 | 1.236 | 1.851 | 1.511 | 1.688 | |
P值 | 0.613 | 0.379 | 0.148 | 0.219 | 0.066 | 0.133 | 0.094 | |
组别 | TC/ (mmol·L-1) | TG/ (mmol·L-1) | CK-MB mass/ (μg·L-1) | LDL-C/ (mmol·L-1) | HD-C/L (mmol/·L-1) | FT3/ (pmol·L-1) | ||
甲亢性心脏组 | 4.05±1.21 | 1.11±0.40 | 3.22±0.91 | 2.06±0.56 | 1.18±0.32 | 7.54±1.32 | ||
单纯甲亢组 | 4.32±1.09 | 1.23±0.35 | 2.94±0.80 | 1.89±0.61 | 1.09±0.34 | 6.58±1.19 | ||
统计值 | 1.377 | 1.875 | 1.92 | 1.705 | 1.601 | 4.487 | ||
P值 | 0.171 | 0.063 | 0.057 | 0.09 | 0.112 | <0.001 | ||
组别 | FT4/(pmol·L-1) | TSH/(mIU·L-1) | TT3/(μg·L-1) | TT4/(μg·L-1) | THRβ1 mRNA | ALCAT1/(ng·L-1) | ||
甲亢性心脏组 | 19.03±4.10 | 1.49±0.46 | 2.57±0.72 | 130.24±24.31 | 4.20±0.63 | 1.39±0.27 | ||
单纯甲亢组 | 16.84±3.87 | 1.73±0.42 | 2.16±0.69 | 114.98±26.07 | 3.45±0.69 | 1.15±0.25 | ||
统计值 | 3.227 | 3.201 | 3.415 | 3.556 | 6.668 | 5.418 | ||
P值 | 0.002 | 0.002 | 0.001 | 0.001 | <0.001 | <0.001 |
项目 | β值 | 标准误 | Wald值 | P值 | OR值(95%CI) |
---|---|---|---|---|---|
甲状腺功能亢进病程 | 0.356 | 0.384 | 0.862 | 0.140 | 1.428(0.403~5.062) |
FT3 | 0.379 | 0.326 | 1.350 | 0.093 | 1.460(0.354~6.025) |
FT4 | 0.579 | 0.343 | 2.851 | 0.071 | 1.785(0.601~5.299) |
TSH | -0.150 | 0.372 | 0.162 | 0.356 | 0.861(0.247~3.001) |
TT3 | 0.220 | 0.401 | 0.301 | 0.201 | 1.246(0.436~3.562) |
TT4 | 0.358 | 0.397 | 0.812 | 0.152 | 1.430(0.511~4.002) |
THRβ1 mRNA | 1.159 | 0.335 | 11.961 | <0.001 | 3.185(1.524~6.658) |
ALCAT1 | 1.312 | 0.341 | 14.795 | <0.001 | 3.712(1.967~7.006) |
常数项 | -6.384 |
项目 | β值 | 标准误 | Wald值 | P值 | OR值(95%CI) |
---|---|---|---|---|---|
甲状腺功能亢进病程 | 0.356 | 0.384 | 0.862 | 0.140 | 1.428(0.403~5.062) |
FT3 | 0.379 | 0.326 | 1.350 | 0.093 | 1.460(0.354~6.025) |
FT4 | 0.579 | 0.343 | 2.851 | 0.071 | 1.785(0.601~5.299) |
TSH | -0.150 | 0.372 | 0.162 | 0.356 | 0.861(0.247~3.001) |
TT3 | 0.220 | 0.401 | 0.301 | 0.201 | 1.246(0.436~3.562) |
TT4 | 0.358 | 0.397 | 0.812 | 0.152 | 1.430(0.511~4.002) |
THRβ1 mRNA | 1.159 | 0.335 | 11.961 | <0.001 | 3.185(1.524~6.658) |
ALCAT1 | 1.312 | 0.341 | 14.795 | <0.001 | 3.712(1.967~7.006) |
常数项 | -6.384 |
THRβ1 mRNA/ALCAT1 | 变量 | OR值(95%CI) | RERI | AP/% | SI | |
---|---|---|---|---|---|---|
单纯甲状腺功能亢进 | 甲亢性心脏病 | |||||
-/- | 27 | 10 | 1 | |||
+/- | 12 | 13 | 2.925(1.032~8.290) | |||
-/+ | 11 | 16 | 3.927(1.869~8.251) | |||
+/+ | 9 | 30 | 9.000(2.719~29.790) | 3.148 | 34.98 | 1.855 |
THRβ1 mRNA/ALCAT1 | 变量 | OR值(95%CI) | RERI | AP/% | SI | |
---|---|---|---|---|---|---|
单纯甲状腺功能亢进 | 甲亢性心脏病 | |||||
-/- | 27 | 10 | 1 | |||
+/- | 12 | 13 | 2.925(1.032~8.290) | |||
-/+ | 11 | 16 | 3.927(1.869~8.251) | |||
+/+ | 9 | 30 | 9.000(2.719~29.790) | 3.148 | 34.98 | 1.855 |
项目 | AUC(95%CI) | 最佳临界值 | 敏感性/% | 特异性/% | Youden指数 |
---|---|---|---|---|---|
THRβ1 mRNA | 0.798(0.721~0.862) | 3.70 | 81.16 | 69.57 | 0.507 |
ALCAT1 | 0.726(0.644~0.799) | 1.31 ng·L-1 | 62.32 | 76.81 | 0.391 |
联合检测 | 0.872(0.805~0.923) | 0.477 | 81.16 | 79.71 | 81.16 |
项目 | AUC(95%CI) | 最佳临界值 | 敏感性/% | 特异性/% | Youden指数 |
---|---|---|---|---|---|
THRβ1 mRNA | 0.798(0.721~0.862) | 3.70 | 81.16 | 69.57 | 0.507 |
ALCAT1 | 0.726(0.644~0.799) | 1.31 ng·L-1 | 62.32 | 76.81 | 0.391 |
联合检测 | 0.872(0.805~0.923) | 0.477 | 81.16 | 79.71 | 81.16 |
[1] |
MCDERMOTT M T. Hyperthyroidism[J]. Ann Intern Med, 2020, 172(7):ITC49-ITC64.
DOI URL |
[2] |
HAN C R, WANG H, HOFFMANN V, et al. Thyroid hormone receptor α mutations cause heart defects in zebrafish[J]. Thyroid, 2021, 31(2):315-326.
DOI URL |
[3] |
LI H, ZENG R L, LIAO Y F, et al. Association of plasma connective tissue growth factor levels with hyperthyroid heart disease[J]. Curr Med Sci, 2021, 41(2):348-355.
DOI PMID |
[4] | 胡卫中, 甘甜, 何婧, 等. 超声心动图及血清NT-proBNP检测对甲亢性心脏病的早期诊断价值[J]. 大连医科大学学报, 2021, 43(6):505-508. |
[5] |
MIKLAS J W, CLARK E, LEVY S, et al. TFPa/HADHA is required for fatty acid beta-oxidation and cardiolipin re-modeling in human cardiomyocytes[J]. Nat Commun, 2019, 10(1):4671.
DOI PMID |
[6] | 孙加凤, 张丽, 彭兴, 等. 血清NT-proBNP、ALCAT1与25(OH)D联合检测在老年甲亢性心脏病患者诊断中的应用价值[J]. 老年医学与保健, 2021, 27(3):598-601. |
[7] |
GAN S, YANG M, FAN L, et al. Triiodothyronine attenuates silica-induced oxidative stress,inflammation,and apoptosis via thyroid hormone receptor α in differentiated THP-1 macrophages[J]. Chem Res Toxicol, 2020, 33(5):1256-1265.
DOI URL |
[8] |
陈晶, 李斌, 宋芳, 等. 母源性甲状腺功能亢进对仔鼠心脏甲状腺激素受体mRNA表达的影响[J]. 解剖学报, 2013, 44(4):546-549.
DOI |
[9] | 中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 甲状腺功能亢进症基层诊疗指南(2019年)[J]. 中华全科医师杂志, 2019, 18(12):1118-1128. |
[10] | 梁爱凤, 龚倩, 阚林. 上海市青浦区健康体检者甲状腺功能检测结果分析[J]. 检验医学与临床, 2020, 17(15):2143-2145. |
[11] |
KIM H J, KANG T, KANG M J, et al. Incidence and mortality of myocardial infarction and stroke in patients with hyperthyroidism:anationwide cohort study in Korea[J]. Thyroid, 2020, 30(7):955-965.
DOI URL |
[12] |
ZHU W Z, OLSON A, PORTMAN M, et al. Sex impacts cardiac function and the proteome response to thyroid hormone in aged mice[J]. Proteome Sci, 2020, 18(1):11.
DOI PMID |
[13] |
LILLEVANG-JOHANSEN M, ABRAHAMSEN B, JØRGENSEN H L, et al. Duration of hyperthyroidism and lack of sufficient treatment are associated with increased cardiovascular risk[J]. Thyroid, 2019, 29(3):332-340.
DOI URL |
[14] |
PILECKY D, VAMOS M, BOGYI P, et al. Risk of cardiac arrhythmias after electrical accident:a single-center study of 480 patients[J]. Clin Res Cardiol, 2019, 108(8):901-908.
DOI |
[15] |
KOTTWITZ J, BRUNO K A, BERG J, et al. Myoglobin for detection of high-risk patients with acute myocarditis[J]. J Cardiovasc Transl Res, 2020, 13(5):853-863.
DOI |
[16] | 韩晓红, 郭志伟, 杨卫红, 等. 饮水型砷暴露人群甲状腺激素受体mRNA的表达及意义[J]. 中华地方病学杂志, 2016, 35(8):552-556. |
[17] |
GEIST D, HÖNES G S, GASSEN J, et al. Noncanonical thyroid hormone receptor α action mediates arterial vasodilation[J]. Endocrinology, 2021, 162(7):bqab099.
DOI URL |
[18] |
SANDSVEDEN M, BORGQUIST S, ROSENDAHL A H, et al. Low thyroid hormone receptor alpha-2(THRα-2) tumor expression is associated with unfavorable tumor characteristics and high breast cancer mortality[J]. Breast Cancer Res, 2021, 23(1):117.
DOI |
[19] |
郎昆, 马峻峰, 王玉明. 甲状腺功能亢进症周期性麻痹死亡病例报告及文献分析[J]. 检验医学, 2019, 34(6):573-576.
DOI URL |
[20] |
TANIZAKI Y, SHIBATA Y, ZHANG H, et al. Analysis of thyroid hormone receptor α-knockout tadpoles reveals that the activation of cell cycle program is involved in thyroid hormone-induced larval epithelial cell death and adult intestinal stem cell development during xenopus tropicalismeta morphosis[J]. Thyroid, 2021, 31(1):128-142.
DOI URL |
[21] |
KNABL J, DE MAIZIERE L, HÜTTENBRENNER R, et al. Cell type- and sex-specific dysregulation of thyroid hormone receptors in placentas in gestational diabetes mellitus[J]. Int J Mol Sci, 2020, 21(11):4056.
DOI URL |
[22] | 原野, 王国坤. 氧化应激相关酶在心血管疾病中的研究进展[J]. 第二军医大学学报, 2021, 42(5):538-542. |
[23] |
SENONER T, DICHTL W. Oxidative stress in cardiovascular diseases:still a therapeutic target?[J]. Nutrients, 2019, 11(9):2090.
DOI URL |
[24] | 谢治丽, 武丽丽, 陈晓晴, 等. 临床甲亢患者左心室舒张功能障碍影响因素分析[J]. 中国心血管病研究, 2022, 20(2):118-122. |
[25] |
JIA D, ZHANG J, NIE J, et al. Cardiolipin remodeling by ALCAT1 links hypoxia to coronary artery disease by promoting mitochondrial dysfunction[J]. Mol Ther, 2021, 29(12):3498-3511.
DOI PMID |
[26] |
WU F, LI Z, CAI M, et al. Aerobic exercise alleviates oxidative stress-induced apoptosis in kidneys of myocardial infarction mice by inhibiting ALCAT1 and activating FNDC5/Irisin signaling pathway[J]. Free Radic Biol Med, 2020, 158:171-180.
DOI URL |
[1] | DAI Hongjian, CUI Haining, LI Yanfeng, CUI Hongmei. Promoting effect of miR-155-5p targeting ARID2 on oral squamous cell carcinoma [J]. Laboratory Medicine, 2024, 39(1): 87-94. |
[2] | YANG Jielin, WANG Xiaoyuan, LI Haixia. Expression and interaction of TRX and TXNIP in colorectal cancer [J]. Laboratory Medicine, 2023, 38(4): 330-336. |
[3] | WANG Yao. Changes of serum thyroid peroxidase antibody and thyroglobulin antibody in patients with hyperthyroidism heart disease [J]. Laboratory Medicine, 2018, 33(9): 790-793. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||